Ranolazine

Generic Name: Ranolazine

Brand Names: Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₃N_₃O_₄

CAS Number: 95635-55-5

Unique Ingredient Identifier: A6IEZ5M406

Background: Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drug...

Indication: Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
...

Associated Conditions: Chronic Angina, Ventricular Arrhythmia

Associated Therapies: -

Clinical Trials

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

Phase 2

Completed

Conditions: Microvascular Angina

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-05-26

Last Posted Date: 2019-05-21

Lead Sponsor: Emory University

Target Recruit Count: 26

Registration Number: NCT02147067

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Phase 4

Completed

Conditions: Pulmonary Hypertension
Diastolic Left Ventricular Dysfunction

Interventions: Drug: Ranolazine

First Posted Date: 2014-05-08

Last Posted Date: 2017-05-17

Lead Sponsor: Boston University

Target Recruit Count: 10

Registration Number: NCT02133352

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy

Phase 2

Completed

Conditions: Dilated Cardiomyopathy

Interventions: Drug: Ranolazine

First Posted Date: 2014-05-08

Last Posted Date: 2021-04-28

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 10

Registration Number: NCT02133911

Locations: 🇸🇮
Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia

Ranolazine and Microvascular Angina by PET in the Emergency Department

Phase 4

Completed

Conditions: Microvascular Angina

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2014-01-31

Last Posted Date: 2017-05-16

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT02052011

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Study to Reduce Symptoms of Premature Beats With Ranolazine

Phase 4

Conditions: Premature Ventricular Beats

Interventions: Drug: Ranolazine

First Posted Date: 2013-11-27

Last Posted Date: 2015-05-01

Lead Sponsor: Walter Reed National Military Medical Center

Target Recruit Count: 72

Registration Number: NCT01996618

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

Not Applicable

Completed

Conditions: Soft Tissue Metastases
Stage IV Prostate Cancer
Stage IIA Prostate Cancer
Stage III Prostate Cancer
Adenocarcinoma of the Prostate
Stage IIB Prostate Cancer
Bone Metastases

Interventions: Drug: Ranolazine

First Posted Date: 2013-11-25

Last Posted Date: 2018-12-03

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 11

Registration Number: NCT01992016

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Effects of Ranolazine and Exercise on Daily Physical Activity Trial

Phase 4

Completed

Conditions: Chronic Stable Angina

Interventions: Behavioral: Aerobic Exercise
Drug: Ranolazine
Drug: Placebo

First Posted Date: 2013-09-23

Last Posted Date: 2017-12-12

Lead Sponsor: Duke University

Target Recruit Count: 38

Registration Number: NCT01948310

Locations: 🇺🇸
Duke Center for Living, Durham, North Carolina, United States

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Phase 2

Terminated

Conditions: Atrial Fibrillation
Heart Failure

Interventions: Drug: Placebo
Drug: Ranolazine

First Posted Date: 2013-06-26

Last Posted Date: 2015-07-20

Lead Sponsor: Intermountain Health Care, Inc.

Target Recruit Count: 8

Registration Number: NCT01887353

Locations: 🇺🇸
Intermountain Medical Center, Murray, Utah, United States

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

Phase 1

Completed

Conditions: Drug-induced Surface ECG Changes

Interventions: Drug: Placebo
Drug: Ranolazine
Drug: Dofetilide
Drug: Verapamil
Drug: Quinidine sulfate

First Posted Date: 2013-06-10

Last Posted Date: 2018-03-08

Lead Sponsor: Food and Drug Administration (FDA)

Target Recruit Count: 22

Registration Number: NCT01873950

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Ranolazine
Drug: Placebo
Drug: Exenatide

First Posted Date: 2013-04-30

Last Posted Date: 2014-03-31

Lead Sponsor: Gilead Sciences

Target Recruit Count: 24

Registration Number: NCT01843127

Locations: 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸
Translational Research Institute-Florida Hospital, Orlando, Florida, United States
🇺🇸
SeaView Research, Inc, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy